- Home
- CHEC vs SGMT Comparison
CHEC vs SGMT Comparison
Compare CHEC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CHEC | SGMT |
|---|---|---|
| Founded | 2024 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 164.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHEC | SGMT |
|---|---|---|
| Price | $10.05 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 128.8K | ★ 486.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.73 |
| 52 Week High | $10.56 | $11.41 |
Technical Indicators
Market Signals| Indicator | CHEC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 51.03 |
| Support Level | $10.02 | $5.60 |
| Resistance Level | $10.56 | $6.72 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 60.40 | 62.78 |
Price Performance
Historical ComparisonAbout CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.